Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus whole-brain radiotherapy versus radiotherapy alone in NSCLC with brain metastases
2004-001749-13Phase 2Terminated
- Sponsor
- AESCA Pharma
- Start
- Dec 2004
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by AESCA Pharma. Primary endpoint: Safety and toxicity. Started Dec 2004; status: terminated.
02
Drugs
temozolomide
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on 2004-001749-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001749-13.